BC Platforms today announces that Pfizer Finland will be using its technology solutions and research platform, including BCRQUEST.COM, to study data in cardiovascular diseases.
(13 Feb, 2018) Basel, Switzerland and Boston, Massachusetts - BC Platforms, a world leader in genomic data management and analytics, today announces that Pfizer Finland will be using its technology solutions and research platform, including BCRQUEST.COM, to study data in cardiovascular diseases. The services will be used to analyze anonymized data from Turku University Hospital and other health care providers to generate real world evidence in atrial fibrillation patients. Microsoft will provide the cloud infrastructure for indexing and accessing the information globally through the Microsoft Azure cloud platform.
Jaakko Parkkinen, Country Medical Director at Pfizer commented, “Cardiovascular diseases are the leading cause of global mortality in the world and the incidence is rising due to an aging population. The diseases are complex and therefore we need data to fully understand and provide the best treatment outcomes for patients. We believe that combining our expertise in treatment of cardiovascular diseases with BC Platforms’ advanced genomic and clinical data management solutions through BCRQUEST.COM
, we can gather and analyse important real world evidence to generate optimal patient outcomes.”
Samu Kurki, lead scientist at BC Platforms commented: ‘Pfizer is one of the leaders in providing treatment solutions for patients suffering from cardiovascular diseases and we are delighted that they have chosen to collaborate with us to support the generation of real world evidence in this space to better understand the complexities of the disease. These types of projects are ideal for leveraging data from innovative healthcare systems to support clinical research and outcomes.’
Pfizer and BC Platforms are both part of the FinnGen project, which is one of the largest global research projects aiming to improve human health through genetic research. The collaborative nature of the project is exceptional and all the partners are working closely together to ensure appropriate transparency, data security and ownership. Finland is leading the field in this space due to its combination of unique genetic heritage, decades of population-wide medical registry data, progressive government legislation and cutting-edge genomics technologies.
